In Vivo Expansion of Co-Transplanted T Cells Impacts on Tumor Re-Initiating Activity of Human Acute Myeloid Leukemia in NSG Mice

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  von Bonin, Malte ^a,b   Wermke, Martin ^b   Cosgun, Kadriye Nehir ^a   Thiede, Christian ^b   Bornhauser, Martin ^b   Wagemaker, Gerard ^c   Waskow, Claudia ^a  

^a CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD3+ T LYMPHOCYTE; CELL EXPANSION; CELL LINEAGE; CHIMERA; DONOR; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOLOGICAL PARAMETERS; POLYCLONAL ACTIVATION; REPRODUCIBILITY; SURVIVAL; T CELL DEPLETION; TUMOR ENGRAFTMENT; TUMOR REINITIATING ACTIVITY; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

ADULT; AGED; ANIMALS; BONE MARROW TRANSPLANTATION; CELL PROLIFERATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MYELOID CELLS; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HETEROLOGOUS; WHOLE-BODY IRRADIATION;

MUS;

EID: 84876026394     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060680     Document Type: Article

References (57)

1. Bosma GC, Custer RP, Bosma MJ, (1983) A Severe Combined Immunodeficiency Mutation in the Mouse. Nature 301: 527-530.
2. Feuring-Buske M, Gerhard B, Cashman J, Humphries RK, Eaves CJ, et al. (2003) Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17: 760-763.
3. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, et al. (2005) Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 106: 1565-1573.
4. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, et al. (1995) Multiple Defects in Innate and Adaptive Immunological Function in Nod/Ltsz-Scid Mice. Journal of Immunology 154: 180-191.
5. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, et al. (2010) AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24: 1785-1788.
6. Dick JE, (2008) Stem cell concepts renew cancer research. Blood 112: 4793-4807.
7. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, et al. (2011) Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19: 138-152.
8. Martelli MP, Pettirossi V, Thiede C, Bonifacio E, Mezzasoma F, et al. (2010) CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood 116: 3907-3922.
9. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, et al. (2011) Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 121: 384-395.
10. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, et al. (2008) Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112: 568-575.
11. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, et al. (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115: 1976-1984.
12. Estey E, Dohner H, (2006) Acute myeloid leukaemia. Lancet 368: 1894-1907.
13. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, et al. (2010) Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 28: 275-280.
14. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ, (1997) Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 89: 3104-3112.
15. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, et al. (2007) CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A 104: 11008-11013.
16. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, et al. (2011) Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A 108: 5009-5014.
17. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, et al. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777-1784.
18. Kikushige Y, Akashi K, (2012) TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia. Ann N Y Acad Sci 1266: 118-123.
19. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, et al. (2010) Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2: 17ra19.
20. van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, et al. (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110: 2659-2666.
21. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326-4335.
22. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, et al. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107: 4011-4020.
23. Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, et al. (2008) The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 9: 676-683.
24. Thiede C, Creutzig E, Illmer T, Schaich M, Heise V, et al. (2006) Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping. Leukemia 20: 1897-1899.
25. Bueno C, Montes R, de la Cueva T, Gutierrez-Aranda I, Menendez P, (2010) Intra-bone marrow transplantation of human CD34(+) cells into NOD/LtSz-scid IL-2rgamma(null) mice permits multilineage engraftment without previous irradiation. Cytotherapy 12: 45-49.
26. Bruggemann M, White H, Gaulard P, Garcia-Sanz R, Gameiro P, et al. (2007) Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 21: 215-221.
27. Du JW, Gu JY, Liu J, Cen XN, Zhang Y, et al. (2007) TCR spectratyping revealed T lymphocytes associated with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 48: 1618-1627.
28. Gorin NC, Piantadosi S, Stull M, Bonte H, Wingard JR, et al. (2002) Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood. J Hematother Stem Cell Res 11: 277-292.
29. Gregoire-Gauthier J, Durrieu L, Duval A, Fontaine F, Dieng MM, et al. (2012) Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/gammac- mouse model. Bone Marrow Transplant 47: 439-450.
30. Hesselton RM, Greiner DL, Mordes JP, Rajan TV, Sullivan JL, et al. (1995) High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J Infect Dis 172: 974-982.
31. King MA, Covassin L, Brehm MA, Racki W, Pearson T, et al. (2009) Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 157: 104-118.
32. Ramirez M, Rottman GA, Shultz LD, Civin CI, (1998) Mature human hematopoietic cells in donor bone marrow complicate interpretation of stem/progenitor cell assays in xenogeneic hematopoietic chimeras. Exp Hematol 26: 332-344.
33. van Rijn RS, Simonetti ER, Hagenbeek A, Hogenes MC, de Weger RA, et al. (2003) A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 102: 2522-2531.
34. Verlinden SF, Mulder AH, de Leeuw JP, van Bekkum DW, (1998) T lymphocytes determine the development of xeno GVHD and of human hemopoiesis in NOD/SCID mice following human umbilical cord blood transplantation. Stem Cells 16Suppl 1: 205-217.
35. Paz Morante M, Briones J, Canto E, Sabzevari H, Martino R, et al. (2006) Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease. Clin Exp Immunol 145: 36-43.
36. King M, Pearson T, Shultz LD, Leif J, Bottino R, et al. (2008) A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin Immunol 126: 303-314.
37. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, et al. (2003) Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 17: 3029-3035.
38. Haase D, Feuring-Buske M, Konemann S, Fonatsch C, Troff C, et al. (1995) Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 86: 2906-2912.
39. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
40. So CW, Karsunky H, Passegue E, Cozzio A, Weissman IL, et al. (2003) MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell 3: 161-171.
41. Martelli MP, Manes N, Pettirossi V, Liso A, Pacini R, et al. (2008) Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML. Leukemia 22: 195-198.
42. Pasqualucci L, Liso A, Martelli MP, Bolli N, Pacini R, et al. (2006) Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood 108: 4146-4155.
43. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, et al. (2008) Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer 123: 2222-2227.
44. Malaise M, Neumeier M, Botteron C, Dohner K, Reinhardt D, et al. (2011) Stable and reproducible engraftment of primary adult and pediatric acute myeloid leukemia in NSG mice. Leukemia 25: 1635-1639.
45. Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, et al. (2009) A robust xenotransplantation model for acute myeloid leukemia. Leukemia 23: 2109-2117.
46. Ailles LE, Gerhard B, Kawagoe H, Hogge DE, (1999) Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 94: 1761-1772.
47. Bonnet D, Dick JE, (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737.
48. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
49. Rombouts WJ, Martens AC, Ploemacher RE, (2000) Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia 14: 889-897.
50. Risueno RM, Campbell CJ, Dingwall S, Levadoux-Martin M, Leber B, et al. (2011) Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease. Blood 117: 7112-7120.
51. Ali N, Flutter B, Sanchez Rodriguez R, Sharif-Paghaleh E, Barber LD, et al. (2012) Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rgammanull mice display a T-effector memory phenotype. PLoS One 7: e44219.
52. Greenblatt MB, Vbranac V, Tivey T, Tsang K, Tager AM, et al. (2012) Graft versus host disease in the bone marrow, liver and thymus humanized mouse model. PLoS One 7: e44664.
53. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-1321.
54. Martin MG, Welch JS, Uy GL, Fehniger TA, Kulkarni S, et al. (2010) Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice. Leukemia 24: 1662-1664.
55. Patel S, Zhang Y, Cassinat B, Zassadowski F, Ferre N, et al. (2012) Successful xenografts of AML3 samples in immunodeficient NOD/shi-SCID IL2Rgamma(-)/(-) mice. Leukemia 26: 2432-2435.
56. Yoshida S, Ishikawa F, Yasukawa M, Miyamoto T, Yoshimoto G, et al. (2005) Long-term engraftment and self-renewal of AML stem cells in the newborn NOD-scid/IL2rgmll immumodeficient mouse model. Blood 106: 367A-367A.
57. Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, et al. (2011) A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 117: 5463-5472.